Genotype-phenotype correlations in Graves' disease.

[1]  A. Lewiński,et al.  Significance of HLA in the development of Graves’ orbitopathy , 2023, Genes & Immunity.

[2]  A. Leung,et al.  Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association , 2022, European thyroid journal.

[3]  H. Y. Ahn,et al.  Predictive model for Graves' ophthalmopathy in patients with new-onset Graves' disease. , 2022, Thyroid : official journal of the American Thyroid Association.

[4]  Jin-an Zhang,et al.  Polymorphisms of ATG5 Gene Are Associated with Autoimmune Thyroid Diseases, Especially Thyroid Eye Disease , 2022, Journal of immunology research.

[5]  Y. Tomer,et al.  Genetics and epigenetics of autoimmune thyroid diseases: Translational implications. , 2022, Best practice & research. Clinical endocrinology & metabolism.

[6]  J. Vrbíková,et al.  Recurrence of Graves’ Disease: What Genetics of HLA and PTPN22 Can Tell Us , 2021, Frontiers in Endocrinology.

[7]  P. Åsman,et al.  Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres , 2021, Endocrine.

[8]  W. Wiersinga,et al.  THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY. , 2021, European journal of endocrinology.

[9]  Y. Tomer,et al.  Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody , 2021, Frontiers in Endocrinology.

[10]  F. Gianfagna,et al.  Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression , 2020, Journal of Endocrinological Investigation.

[11]  M. Mahmoudi,et al.  Graves' disease: introducing new genetic and epigenetic contributors. , 2020, Journal of molecular endocrinology.

[12]  G. Kahaly.  Management of Graves Thyroidal and Extrathyroidal Disease: An Update , 2020, The Journal of clinical endocrinology and metabolism.

[13]  S. Pearce,et al.  New Therapeutic Horizons for Graves’ Hyperthyroidism , 2020, Endocrine reviews.

[14]  C. Khoo,et al.  Prevalence of thyroid eye disease in Graves’ disease: A meta‐analysis and systematic review , 2020, Clinical endocrinology.

[15]  G. Barbesino,et al.  Graves’ disease , 2020, Nature Reviews Disease Primers.

[16]  H. Cordell,et al.  An Intronic HCP5 Variant Is Associated With Age of Onset and Susceptibility to Graves Disease in UK and Polish Cohorts , 2020, The Journal of clinical endocrinology and metabolism.

[17]  R. Murray,et al.  Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study , 2019, Thyroid : official journal of the American Thyroid Association.

[18]  W. Cho,et al.  HLA alleles, especially amino-acid signatures of HLA-DPB1, might contribute to the molecular pathogenesis of early-onset autoimmune thyroid disease , 2019, PloS one.

[19]  G. Novelli,et al.  STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjögren's Syndrome: Association with Disease Susceptibility and Clinical Aspects , 2019, Journal of immunology research.

[20]  R. Płoski,et al.  Paediatric‐onset and adult‐onset Graves' disease share multiple genetic risk factors , 2018, Clinical endocrinology.

[21]  D. Valverde,et al.  Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value , 2018, Endocrine.

[22]  P. Taylor,et al.  Global epidemiology of hyperthyroidism and hypothyroidism , 2018, Nature Reviews Endocrinology.

[23]  S. Pearce,et al.  2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism , 2018, European Thyroid Journal.

[24]  W. Wiersinga,et al.  Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management , 2018, Journal of Endocrinological Investigation.

[25]  L. Hegedüs,et al.  Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. , 2018, European journal of endocrinology.

[26]  W. Teng,et al.  Alterations of Global DNA Methylation and DNA Methyltransferase Expression in T and B Lymphocytes from Patients with Newly Diagnosed Autoimmune Thyroid Diseases After Treatment: A Follow-Up Study. , 2018, Thyroid : official journal of the American Thyroid Association.

[27]  Wei Liu,et al.  Genetic study of early‐onset Graves’ disease in the Chinese Han population , 2018, Clinical genetics.

[28]  A. Krętowski,et al.  Analysis of chosen polymorphisms rs2476601 a/G – PTPN22, rs1990760 C/T – IFIH1, rs179247 a/G – TSHR in pathogenesis of autoimmune thyroid diseases in children , 2018, Autoimmunity.

[29]  Z. Xin,et al.  A genome-wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves’ orbitopathy , 2018, Journal of Endocrinological Investigation.

[30]  Samsuridjal Djauzi,et al.  The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease. , 2017, Acta medica Indonesiana.

[31]  Guang Wang,et al.  Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease , 2017, Front. Endocrinol..

[32]  W. Cho,et al.  Association of Polymorphisms in Toll-Like Receptors 4 and 9 with Autoimmune Thyroid Disease in Korean Pediatric Patients , 2017, International journal of endocrinology.

[33]  S. Balasubramanian,et al.  Epidemiology, management and outcomes of Graves’ disease—real life data , 2017, Endocrine.

[34]  R. Płoski,et al.  Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves’ ophthalmopathy , 2016, Journal of Human Genetics.

[35]  P. White,et al.  Graves' disease in children: long‐term outcomes of medical therapy , 2016, Clinical endocrinology.

[36]  M. Bolanowski,et al.  CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease , 2016, Endocrine.

[37]  K. Badenhoop,et al.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers , 2016, Reviews in Endocrine and Metabolic Disorders.

[38]  E. J. Lee,et al.  Role of miR-146a in the Regulation of Inflammation in an In Vitro Model of Graves' Orbitopathy. , 2016, Investigative ophthalmology & visual science.

[39]  G. Montgomery,et al.  Association of Polymorphisms in MACRO Domain Containing 2 With Thyroid-Associated Orbitopathy. , 2016, Investigative ophthalmology & visual science.

[40]  F. Lo,et al.  Association of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) Gene Polymorphisms with Autoimmune Thyroid Disease in Children and Adults: Case-Control Study , 2016, PLoS ONE.

[41]  A. Zwinderman,et al.  Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. , 2016, The Journal of clinical endocrinology and metabolism.

[42]  Terry J. Smith,et al.  Graves' Disease. , 2016, The New England journal of medicine.

[43]  S. Sanna,et al.  The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves' disease , 2015, Clinical endocrinology.

[44]  D. Ye,et al.  Emerging role of long noncoding RNAs in autoimmune diseases. , 2015, Autoimmunity reviews.

[45]  Huaxi Xu,et al.  MiR-346 regulates CD4+CXCR5+ T cells in the pathogenesis of Graves’ disease , 2015, Endocrine.

[46]  R. Secolin,et al.  TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves’ disease and Graves’ ophthalmopathy , 2015, Journal of Endocrinological Investigation.

[47]  Weiqing Wang,et al.  Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves’ ophthalmopathy , 2015, Endocrine.

[48]  G. Novelli,et al.  A Multilocus Genetic Study in a Cohort of Italian SLE Patients Confirms the Association with STAT4 Gene and Describes a New Association with HCP5 Gene , 2014, PloS one.

[49]  F. Tsai,et al.  Single nucleotide polymorphisms at the PRR3, ABCF1, and GNL1 genes in the HLA class I region are associated with Graves' ophthalmopathy in a gender-dependent manner. , 2014, Ophthalmology.

[50]  P. Laurberg,et al.  Relapse following antithyroid drug therapy for Graves’ hyperthyroidism , 2014, Current opinion in endocrinology, diabetes, and obesity.

[51]  R. Płoski,et al.  Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy , 2014, PloS one.

[52]  Xiaojie Ma,et al.  Associations of CTLA4 Gene Polymorphisms with Graves' Ophthalmopathy: A Meta-Analysis , 2014, International journal of genomics.

[53]  W. Wiersinga,et al.  Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. , 2014, European journal of endocrinology.

[54]  M. Szalecki,et al.  Analysis of chosen polymorphisms in FoxP3 gene in children and adolescents with autoimmune thyroid diseases , 2014, Autoimmunity.

[55]  Vaneet Lotay,et al.  Genetic analysis in young-age-of-onset Graves' disease reveals new susceptibility loci. , 2014, The Journal of clinical endocrinology and metabolism.

[56]  Yaoming Xue,et al.  Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. , 2014, Endocrine journal.

[57]  A. Kucharska,et al.  CTLA-4 polymorphisms (+49 A/G and -318 C/T) are important genetic determinants of AITD susceptibility and predisposition to high levels of thyroid autoantibodies in Polish children - preliminary study. , 2013, Acta biochimica Polonica.

[58]  S. Jansson,et al.  Incidence rate and clinical features of hyperthyroidism in a long‐term iodine sufficient area of Sweden (Gothenburg) 2003–2005 , 2013, Clinical endocrinology.

[59]  M. Bolanowski,et al.  PPARg2 Ala12 variant protects against Graves' orbitopathy and modulates the course of the disease , 2013, Immunogenetics.

[60]  R. Płoski,et al.  Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response , 2013, PloS one.

[61]  M. Watanabe,et al.  Association of polymorphisms in DNMT1, DNMT3A, DNMT3B, MTHFR and MTRR genes with global DNA methylation levels and prognosis of autoimmune thyroid disease , 2012, Clinical and experimental immunology.

[62]  F. Lo,et al.  The HLA-DRB1 gene and Graves disease in Taiwanese children: a case-control and family-based study. , 2012, Tissue antigens.

[63]  R. Latif,et al.  Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy. , 2012, Thyroid : official journal of the American Thyroid Association.

[64]  L. Seah,et al.  Ethnic differences in the clinical presentation of Graves' ophthalmopathy. , 2012, Best practice & research. Clinical endocrinology & metabolism.

[65]  S. Juo,et al.  Genotype and Phenotype Predictors of Relapse of Graves’ Disease after Antithyroid Drug Withdrawal , 2012, European Thyroid Journal.

[66]  W. Cho,et al.  Association of HLA Alleles with Autoimmune Thyroid Disease in Korean Children , 2011, Hormone Research in Paediatrics.

[67]  Yang Liu,et al.  Genome-Wide Interaction-Based Association Analysis Identified Multiple New Susceptibility Loci for Common Diseases , 2011, PLoS genetics.

[68]  A. Esteghamati,et al.  Genetic susceptibility to Graves’ ophthalmopathy: the role of polymorphisms in proinflammatory cytokine genes , 2010, Eye.

[69]  S. Greene,et al.  Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland , 2010, Clinical endocrinology.

[70]  R. Bahn.  Graves' ophthalmopathy. , 2010, The New England journal of medicine.

[71]  A. Esteghamati,et al.  Graves' ophthalmopathy and gene polymorphisms in interleukin‐1α, interleukin‐1β, interleukin‐1 receptor and interleukin‐1 receptor antagonist , 2009, Clinical & experimental ophthalmology.

[72]  N. Morgenthaler,et al.  The T393C polymorphism of the Galphas gene (GNAS1) is associated with the course of Graves' disease. , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[73]  P. Czernichow,et al.  Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. , 2008, The Journal of clinical endocrinology and metabolism.

[74]  Ya-Ting Chang,et al.  Association of CT60 Polymorphism of the CTLA4 Gene with Graves' Disease in Taiwanese Children , 2008, Journal of pediatric endocrinology & metabolism : JPEM.

[75]  K. Park,et al.  Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease. , 2007, Thyroid : official journal of the American Thyroid Association.

[76]  J. Franklyn,et al.  Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves’ ophthalmopathy , 2007, Clinical endocrinology.

[77]  M. Hsieh,et al.  Association between a C/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves' hyperthyroidism after antithyroid withdrawal in Taiwanese. , 2007, The Journal of clinical endocrinology and metabolism.

[78]  S. Juo,et al.  Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: a follow-up study. , 2007, The Journal of clinical endocrinology and metabolism.

[79]  R. Płoski,et al.  Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack? , 2007, Clinical endocrinology.

[80]  H. Issever,et al.  The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of graves’ disease after antithyroid withdrawal , 2006, Endocrine.

[81]  M. Erdoğan,et al.  Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy. , 2005, European journal of internal medicine.

[82]  R. Płoski,et al.  Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves’ disease in a Polish population: association and gene dose‐dependent correlation with age of onset , 2005, Clinical endocrinology.

[83]  K. Jażdżewski,et al.  Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. , 2004, Human immunology.

[84]  A. Krętowski,et al.  Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. , 2003, The Journal of clinical endocrinology and metabolism.

[85]  F. Lo,et al.  Polymorphism in the transmembrane region of the major histocompatibility complex class I chain-related gene A: association of five GCT repetitions with Graves' disease in children. , 2003, Thyroid : official journal of the American Thyroid Association.

[86]  P. Perros,et al.  CTLA4 gene and Graves’ disease: association of Graves’ disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism , 2003, Clinical endocrinology.

[87]  T. Kouki,et al.  Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. , 2002, The Journal of clinical endocrinology and metabolism.

[88]  L. Hegedüs,et al.  Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. , 2001, The Journal of clinical endocrinology and metabolism.

[89]  T. Bednarczuk,et al.  A polymorphism of the 5′ flanking region of tumour necrosis factor α gene is associated with thyroid‐associated ophthalmopathy in Japanese , 2000, Clinical endocrinology.

[90]  J. Franklyn,et al.  The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. , 1999, The Journal of clinical endocrinology and metabolism.

[91]  H. Perrild,et al.  Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. , 1994, European journal of endocrinology.

[92]  R. Holle,et al.  Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. , 1989, Acta endocrinologica.